Entry point of machine learning in axial spondyloarthritis

RMD Open. 2024 Feb 15;10(1):e003832. doi: 10.1136/rmdopen-2023-003832.

Abstract

Axial spondyloarthritis (axSpA) is a globally prevalent and challenging autoimmune disease. Characterised by insidious onset and slow progression, the absence of specific clinical manifestations and biomarkers often leads to misdiagnosis, thereby complicating early detection and diagnosis of axSpA. Furthermore, the high heterogeneity of axSpA, its complex pathogenesis and the lack of specific drugs means that traditional classification standards and treatment guidelines struggle to meet the demands of personalised treatment. Recently, machine learning (ML) has seen rapid advancements in the medical field. By integrating large-scale data with diverse algorithms and using multidimensional data, such as patient medical records, laboratory examinations, radiological data, drug usage and molecular biology information, ML can be modelled based on real-world clinical issues. This enables the diagnosis, stratification, therapeutic efficacy prediction and prognostic evaluation of axSpA, positioning it as an emerging research topic. This study explored the application and progression of ML in the diagnosis and therapy of axSpA from five perspectives: early diagnosis, stratification, disease monitoring, drug efficacy evaluation and comorbidity prediction. This study aimed to provide a novel direction for exploring rational diagnostic and therapeutic strategies for axSpA.

Keywords: Autoimmune Diseases; Machine Learning; Spondylitis, Ankylosing.

Publication types

  • Review

MeSH terms

  • Axial Spondyloarthritis*
  • Humans
  • Machine Learning
  • Prognosis
  • Spondylarthritis* / diagnosis
  • Spondylarthritis* / drug therapy
  • Spondylarthritis* / epidemiology
  • Spondylitis, Ankylosing* / drug therapy